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Abstract
Objective: Osteocalcin (OC), a bone-derived protein, has been implicated in the regulation of glucose and energy
metabolism. Young adults born with very low birth weight (VLBW) have altered glucose regulation and lower bone mineral
density (BMD) compared with those born at term. The aim of this study was to explore the association between bone and
glucose metabolism in healthy young adults born prematurely or at term.
Methods: The cohort of this cross-sectional study comprised 332 non-diabetic young adults (age 18 to 27 years) born either
preterm with VLBW (n= 163) or at term (n = 169). OC, carboxylated osteocalcin (cOC) and markers of glucose metabolism
were measured at fasting and after a 75-g oral glucose tolerance test (OGTT).
Results: VLBW adults were shorter, had lower BMD (p,0.001) and higher fasting OC (p = 0.027) and cOC (p = 0.005) than
term-born subjects. They also had higher 2-hour insulin (p = 0.001) and glucose (p = 0.037) concentrations. OGTT induced a
significant reduction in OC (p,0.001), similar in both groups. OC reduction was not associated with OGTT-induced increases
in insulin (p = 0.54). However, fasting total OC and cOC correlated negatively with fasting insulin after adjustment for age,
gender, BMD and VLBW status (r =20.182, p = 0.009 and r =20.283, p,0.001, respectively).
Conclusion: Adults born with VLBW have higher OC and cOC than their peers born at term. This may in part reflect the
mechanisms that underlie their lower BMD and decreased insulin sensitivity. Serum OC appears to be negatively associated
with long-term glucose regulation whereas acute changes during OGTT may be mediated via other mechanisms.
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Introduction
Glucose homeostasis depends on a complex signal network
orchestrated by the pancreatic islet cells, liver, fat, muscle, kidney
and brain. The role of the skeleton in glucose and energy
homeostasis has recently gained much attention [1,2,3]. The
osteoblast-specific protein osteocalcin (OC) has been recognized as
an endocrine factor with a proposed role in the regulation of
glucose and energy metabolism by influencing insulin secretion
and insulin sensitivity [4,5,6]. Vitamin K –dependent post-
translational c-carboxylation of OC leads to formation of
carboxylated OC whereas only the uncarboxylated form of OC
has been indicated in some studies to induce expression of
adiponectin, insulin, and markers of pancreatic islet cell prolifer-
ation [5].
Preliminary data indicate that the cross-talk between bone and
glucose-insulin metabolism could in part be mediated by OC [7].
Presence of such regulatory pathways in humans has not yet been
confirmed [8], even if the body of knowledge is constantly
increasing [9]. An inverse association between OC and markers of
metabolic dysfunction has been reported in clinical studies
evaluating markers of impaired glucose regulation
[10,11,12,13,14]. While some of the reported associations are
relatively strong, no direct causal relationship between changes in
glucose regulation, insulin sensitivity and changes in OC has been
confirmed in humans. The published studies include mostly cross-
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sectional post hoc analyses of elderly populations with confounding
factors related to high age and co-morbidities such as type 2
diabetes, impaired glucose tolerance or dyslipidemia, which
complicate analysis and interpretation of results [15,16,17].
However, the limited human data regarding the role of OC
carboxylation are inconclusive [9].
Young adults born preterm with very low birth weight (VLBW),
while mostly normoglycemic, have lower insulin sensitivity when
compared with those born at term [18,19]. They also have lower
bone mineral density (BMD) than their peers born at term, when
studied close to the age of peak bone mass attainment [20]. The
developmental period that differs most dramatically between the
VLBW and term-borns occurs after VLBW birth, during the
period that would normally be the third trimester of pregnancy.
This period is important for the development and adjustment of
endocrine and metabolic systems, probably through metabolic
programming, even if the exact mechanisms are unknown
[21,22,23]. This time is also crucial for fetal bone mineralization
as up to 80% of the body calcium of a term newborn is being
accrued during the last trimester [24]. The alterations in skeletal
health and glucose tolerance observed in VLBW subjects in early
adulthood provide an opportunity to further study the regulatory
pathways between glucose, insulin and bone metabolism.
The aim of this study was to explore the association between
bone and glucose metabolism by evaluating OC, carboxylated
osteocalcin (cOC) and markers of glucose and insulin metabolism
before and during a standard oral glucose tolerance test in
apparently healthy young adults born either prematurely with
VLBW or at term.
Materials and Methods
Ethics Statement
The Helsinki and Uusimaa Hospital District Ethics committee
approved the study protocol and a written informed consent was
given by all study participants. The study was carried out
according to the principles of Declaration of Helsinki.
Subjects
The original study cohort comprised 335 consecutive prema-
turely born (gestational age ,37 weeks) VLBW infants born
between January 1978 and December 1985 who were discharged
alive from the neonatal intensive care unit of Children’s Hospital
at Helsinki University Central Hospital, Finland. A comparison
group was selected from the records of all consecutive births at
each birth hospital. For each VLBW survivor, the next available
singleton infant born at term (gestational age $37 weeks) of the
same sex who was not small for gestational age (standard-deviation
score for birth weight $22.0) was selected. The subjects were
traced in young adulthood in 2004 through data from the
Population Register Centre of Finland. Mortality from hospital
discharge to June 2004 was 1.8% for the VLBW subjects and 1.0%
for the comparison group born at term. Birth weight ranged from
600 to 1500 g in the VLBW group and from 2560 to 4930 g in the
Table 1. Characteristics of the study population (n = 332).
Term VLBW p value
Subjects, n 169 163
Gender, M/F 68/101 71/92 0.54
Gestational age, weeks 40.1 (1.2) 29.2 (2.2) ,0.001
Birth weight, g 3585.7 (467.7) 1122.3 (220.5) ,0.001
Age at study assessment, years 22.5 (2.2) 22.4 (2.1) 0.93
Height, cm M 180.5 (6.4) 174.6 (7.7) ,0.001
F 167.2 (6.8) 162.0 (7.6) ,0.001
Weight, kg M 76.1 (67.2) 67.2 (13.1) ,0.001
F 63.5 (10.8) 58.5 (12.0) 0.002
BMI, kg/m2 M 23.3 (3.2) 22.0 (3.6) 0.022
F 22.7 (3.7) 22.3 (3.9) 0.41
Lumbar spine aBMD,
Z-score
20.42 (1.05) 20.94 (0.98) ,0.001
Leisure time exercise frequency, n (%) 0.084
None 4 (2.4) 11 (6.7)
Less than once per month 19 (11.2) 12 (12.9)
Once or twice a month 16 (9.5) 22 (13.5)
Once a week 33 (19.5) 31 (19.0)
2 to 3 times a week 63 (37.3) 42 (25.8)
4 to 5 times a week 18 (10.7) 17 (10.4)
Daily 16 (9.5) 15 (9.2)
Not known 0 (0) 4 (2.5)
Education level of more educated parent at least university degree 48.2% 36.2% 0.067
Values are mean (SD) and the p values are for the difference between Term and VLBW groups with one-way ANOVA or Pearson’s chi-square test. Significant p values are
shown in bold. DXA results were available for 284/332 participants.
doi:10.1371/journal.pone.0063036.t001
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term group; gestational age ranged from 24.0 to 35.6 weeks in the
VLBW group and from 37.0 to 42.9 weeks in the term group.
Among the survivors, 95.1% of VLBW subjects and 96.8% of
subjects born at term were identified at young adulthood. A total
of 255 VLBW subjects and 314 subjects born at term who were
living in the greater Helsinki area were invited to participate in the
study. A total of 338 subjects agreed to participate; 166 of the
VLBW subjects (65.1%) and 172 of the subjects born at term
(54.8%). Subjects with type 1 diabetes (n = 1), concomitant or
chronic systemic glucocorticoid use (n = 1), pregnancy (n= 2) or
insufficient fasting prior to OGTT (n= 2) were excluded from the
analyses. After exclusions altogether 332 subjects were eligible for
the study (Table 1).
Clinical Characteristics
All 332 subjects were invited to attend the clinic at the National
Public Health Institute after an overnight fast of at least 10 hours.
For five subjects the overnight fasting period was 7–10 hours but
they were included in the analysis. The subjects were evaluated for
anthropometry (weight, height, body mass index; BMI), medical
history (including self-reported parents’ history of type 1 and type
2 diabetes), leisure-time physical activity and socioeconomic status,
as previously described [18,20].
Oral Glucose Tolerance Test (OGTT)
A 2-hour OGTT (75 g glucose) was initiated between 6:13 am
and 11:11 am. Plasma and serum samples were collected at
baseline (0 min) and at 120 min according to standard protocols.
Plasma glucose concentrations were measured at 0 min and
120 min by spectrophotometric hexokinase and glucose-6-phos-
phate dehydrogenase assay (Gluko-quant glucose/hexokinase,
Roche Diagnostics) with a Hitachi Modular automatic analyzer.
At glucose concentration of 4.7 mmol per liter (84.7 mg per
deciliter), the inter-assay coefficient of variation is 2.3% [25].
Impaired glucose tolerance was defined according to WHO as
plasma glucose concentration .6.1 but #7.0 mmol/l at 0 min
and/or $7.8 mmol/l but ,11.1 mmol/l at 120 min. Diabetes
was defined as plasma glucose concentration $7.0 mmol/l at
0 min and/or $11.1 mmol/l at 120 min. Based on OGTT
findings, all subjects were considered normoglycemic. Serum
samples were stored at 270uC until further analysis.
Measurement of Insulin and HOMA-IR
Serum insulin was measured with time-resolved immunofluoro-
metric assay (Perkin Elmer Life Sciences, Finland) with a detection
limit of 0.5 mU per liter (3 pmol per liter) and an interassay
coefficient of variation of less than 4%. The insulin-resistance
index determined by homeostasis model assessment (HOMA-IR)
was calculated as the product of the fasting serum insulin
concentration (in milliunits per liter) and fasting plasma glucose
concentration (in millimoles per liter) divided by 22.5 [26].
Serum Osteocalcin
Serum total OC and serum c-carboxylated osteocalcin (cOC)
were determined at 0 min and 120 min by previously described
two-site immunoassay protocols [27]. Two site immunoassay for
serum total OC is based on monoclonal antibodies (Mabs) 2H9
and 6F9 and detects the N-terminal midsegment of the OC
molecule. Assay for carboxylated OC (cOC; Mabs 6F9 and 3H8)
detects the same fragments but prefers c-carboxyglutamic acid
(Gla) containing forms of OC, with ,10% cross-reactivity to fully
uncarboxylated OC (ucOC) [28]. Briefly, 200 ng of biotinylated
capture Mab and 100 ng of europium-labelled tracer Mab per
well was used. Synthetic peptide of human OC amino acids 1–49
(Advanced Chemtech, USA) was used as a calibrator. Streptavi-
din-coated microtiter plates were from Kaivogen (Turku, Finland)
and other immunoassay reagents (DelfiaH Assay Buffer, Wash
Solution and Enhacement solution) from Perkin Elmer Life
Sciences (Turku, Finland). Time-resolved fluorescence was mea-
sured with Victor2 Multilabel Counter (PerkinElmer Life Scienc-
es). All samples were measured as duplicates and simultaneously at
the end of the study. In order to reduce the bias by inter-assay
variability, samples for each subject (0 min and 120 min) were
Table 2. Serum levels of insulin, glucose, and osteocalcin
before (fasting) and after (120 min) OGTT in the Term and
VLBW groups.
Term VLBW
p
value
Glucose (mmol/L) Fasting All 4.7 (1.1) 4.7 (1.1) 0.244
M 4.9 (1.1) 4.9 (1.1) 0.874
F 4.5 (1.1) 4.6 (1.1) 0.233
120 min All 5.1 (1.3) 5.3 (1.3) 0.037
M 4.9 (1.3) 5.2 (1.2) 0.167
F 5.2 (1.3) 5.5 (1,3) 0.097
D120 min(%) 11.6% 16.1% 0.259
Insulin (mU/L) Fasting All 5.1 (1.7) 5.6 (1.7) 0.068
M 5.2 (1.8) 5.4 (1.6) 0.671
F 5.0 (1.7) 5.8 (1.7) 0.045
120 min All 26.2 (2.2) 34.1 (1.9) 0.001
M 20.2 (2.6) 26.8 (1.8) 0.032
F 31.2 (1.9) 41.1 (1.9) 0.003
D120 min(%) 545% 625% 0.065
HOMA-IR Fasting All 1.0 (1.8) 1.2 (1.7) 0.060
M 1.1 (1.9) 1.2 (1.6) 0.661
F 1.0 (1.8) 1.2 (1.8) 0.042
Total osteocalcin
(ng/mL)
Fasting all 11.3 (1.5) 12.4 (1.5) 0.027
M 14.0 (1.4) 14.6 (1.4) 0.468
F 9.8 (1.5) 11.0 (1.4) 0.030
120 min all 9.1 (1.5) 10.2 (1.5) 0.016
M 11.5 (1.3) 12.2 (1.4) 0.249
F 7.8 (1.5) 8.9 (1.5) 0.028
D120 min(%) 218.1% 216.7% 0.515
Carboxylated
osteocalcin (ng/mL)
Fasting all 10.6 (1.5) 12.0 (1.5) 0.005
M 12.9 (1.4) 14.2 (1.5) 0.117
F 9.2 (1.5) 10.5 (1.5) 0.021
120 min all 8.5 (1.5) 9.6 (1.5) 0.007
M 10.3 (1.4) 11.8 (1.5) 0.043
F 7.4 (1.5) 8.3 (1.5) 0.061
D120 min(%) 218.8% 218.2% 0.896
Values are geometric means (SD) and the p values are for the difference
between Term and VLBW groups with one-way ANOVA (after logarithmic
transformation) or Mann-Whitney nonparametric test (%-changes). Results are
shown for the entire cohort (n = 331) and for males (n = 138) and females
(n = 193) separately. Significant p values are shown in bold. HOMA-IR was
calculated as Fasting Insulin * Fasting Glucose divided by 22.5.
doi:10.1371/journal.pone.0063036.t002
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analyzed in parallel. The intra- and inter-assay variations were
4.4% and 9.0%, for total OC and 2.5% and 8.0% for cOC,
respectively. Due to lack of validated method for accurate analysis
of ucOC values we used a calculated value for uncarboxylated
OC, which was derived from total OC and cOC values
(ucOC= total OC minus cOC).
Bone Densitometry
Bone mineral content (BMC) and areal BMD (aBMD) for the
lumbar spine (L1–L4) were measured with dual-energy X-ray
absorptiometry (DXA, Hologic Discovery A, software version
12.3:3) and transformed into age-adjusted Z scores using the
equipment-, age-, and sex-specific reference data. A cut-off Z score
value of 21.0 was chosen to define reduced BMD [29]. Body
composition, including lean body mass and fat percent (fat-%), was
determined with the same DXA equipment.
A total of 284 subjects (of 332) were available for the analysis of
lumbar spine aBMD, which was chosen as the site for analysis due
to its high content of trabecular bone and active turnover. The
reasons for the missing BMD results included unwillingness to
undergo DXA, pregnancy, cerebral palsy, several compressed
lumbar vertebrae or foreign objects in the scanning area. Scans
Figure 1. Glucose (A), insulin (B), total osteocalcin (C) and carboxylated osteocalcin (D) before and after 2-hour oral glucose
tolerance test in term and VLBW subjects. The lines inside the boxes represent the 50th percentile; the limits of the boxes represent the 25th
and 75th percentiles, and the whiskers represent the 10th and 90th percentiles.
doi:10.1371/journal.pone.0063036.g001
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with foreign objects such as surgical fixation material or jewelry in
the measurement area (five subjects) were omitted from the
analysis. If more than one lumbar vertebra was compressed, the
corresponding lumbar spine scan was excluded from analysis (two
subjects); if only one lumbar vertebra was compressed, BMD
without the affected vertebra was used (seven subjects).
Statistical Analysis
Glucose, insulin and osteocalcin concentrations and HOMA-IR
were non-normally distributed (Shapiro-Wilk test,0.95) and were
used after logarithmic transformation. The difference between
Term and VLBW groups was analyzed with one-way ANOVA.
Standardized linear regression coefficients (bstd) between the
analytes or the 120 min changes in the analytes were determined
using linear regression. Multiple regression analysis was used to
Figure 2. Standardized linear regression coefficients (bstd) between fasting insulin and A) total osteocalcin or B) carboxylated
osteocalcin. Results are shown separately for the entire cohort (All) and the two groups (Term, VLBW) and they have been adjusted for age, gender
and Z-score for lumbar spine BMD. Squares indicate the value for bstd, and the whiskers represent 95% confidence interval. The P values are
indicated with asterisks: *, P,0.05; **, P,0.01; ***, P,0.001; ns, not significant.
doi:10.1371/journal.pone.0063036.g002
Table 3. Correlations between osteocalcin and parameters of glucose metabolism.
Fasting (0 min) Insulin 120 min Glucose
Betastd +/295% CI p value Betastd +/295% CI p value
Total osteocalcin
Unadjusted 20.103 20.211, 0.005 0.063 20.127 20.235, 20.019 0.021
adj. age, gender, VLBW 20.214 20.340, 20.089 ,0.001 20.128 20.258, 0.002 0.053
adj. age, gender, VLBW, lumbar spine BMD 20.182 20.319, 20.045 0.009 20.099 20.241, 0.042 0.168
adj. age, gender, VLBW, lean body mass 20.156 20.386, 20.031 0.021 20.100 20.144, 0.025 0.850
adj. age, gender, VLBW, fat-% 20.107 20.312, 0.025 0.096 20.044 20.111, 0.058 0.535
Carboxylated osteocalcin
Unadjusted 20.169 20.276, 20.006 0.002 20.117 20.225, 20.009 0.034
adj. age, gender, VLBW 20.312 20.435, 20.190 ,0.001 20.117 20.245, 0.010 0.071
adj. age, gender, VLBW, lumbar spine BMD 20.283 20.418, 20.149 ,0.001 20.090 20.230, 0.049 0.202
adj. age, gender, VLBW, lean body mass 20.242 20.480, 20.143 ,0.001 20.086 20.129, 0.030 0.224
adj. age, gender, VLBW, fat-% 20.144 20.350, 20.030 0.028 20.006 20.084, 0.077 0.938
Values are standardized linear regression coefficients (Betastd) with 95% confidence intervals (CI). Statistically significant values are bolded. Fasting osteocalcin values
were used to evaluate association to fasting insulin and 2-hour osteocalcin values were used to study association to 2-hour glucose values.
doi:10.1371/journal.pone.0063036.t003
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adjust for age, gender, VLBW status or BMD. We used SPSS for
Windows 16.0 (SPSS Inc., Chicago, IL) for statistical analyses,
except for linear regression which were calculated using Statistica
for Windows 7.1 (StatSoft Inc., Tulsa, OK). P values ,0.05 were
considered statistically significant.
Results
The cohort comprised 332 young Finnish adults born either
with VLBW (n= 163; 92 females, 71 males) or at term (n= 169;
101 females, 68 males). The age of the subjects ranged from 18 to
27 years in both groups. There was no difference in age between
the groups at the time of evaluation (mean age 22.4 vs. 22.5 years
for VLBW subjects and those born at term, respectively, p = 0.93).
The mean (6 SD) birth weight in the VLBW group was 1122.7 g
(217.6) and 3570.8 g (520.8) for subjects born at term. The mean
adult weight, height and BMD were significantly lower in subjects
born with VLBW than in those born at term.
Fasting glucose and insulin concentrations were within normal
ranges in both groups but insulin levels were marginally higher in
VLBW subjects (+11%, p= 0.068) when compared to those born
at term. This difference between groups was also statistically
significant between the female VLBW subjects and their term-
born peers as the VLBW females had higher baseline insulin
values than their term-born controls (5.8 vs. 5.0 mU/L, p= 0.045).
There was no difference in fasting glucose levels between the
groups (p = 0.24) or between the genders (Table 2). In contrast, at
120 min all subjects with VLBW had significantly higher insulin
(+30.5%, p= 0.001) and glucose concentrations (+5.5%, p= 0.037)
than those born at term (unadjusted) (Table 2) as previously
reported [18].
Subjects with VLBW had higher fasting levels of OC (ANOVA,
p= 0.027) and cOC (p= 0.005) than the term-born subjects. Total
OC and cOC remained higher also after OGTT in VLBW
subjects as compared with those born at term (ANOVA, p= 0.016
and p= 0.007, respectively) (Table 2, Figure 1). Male subjects had
significantly higher levels of total OC and cOC than female
subjects, both in the VLBW group and in subjects born at term
(p,0.001 for all). The difference between subjects with VLBW
and those born at term tended to be more pronounced in females
but the difference did not reach statistical significance. The mean
lumbar spine Z score values were significantly lower in VLBW
subjects (20.94) than in those born at term (20.42, p,0.001).
Fasting total OC and cOC were negatively correlated with
fasting insulin levels after adjustment for age, gender, VLBW
status and BMD (r =20.182, p = 0.009 and r =20.283, p,0.001,
respectively) (Table 3). The correlation between fasting insulin and
cOC remained significant also after adjustment for lean body mass
(r =20.242, p,0.001) and whole body fat percent (r =20.144,
p = 0.028) (Table 3). The correlation between insulin and OC was
similar in both groups, although the r -values were generally larger
in the VLBW group (Figure 2). There was no significant
association between insulin and total OC when the correlations
were further adjusted for body fat percentage. As expected, total
OC and lumbar spine Z-score were inversely correlated in all
subjects (bstd =20.239, p,0.001) independent of gender or
VLBW status.
The lack of validated methods for the accurate analysis of ucOC
limited the analysis of the ucOC values to the use of theoretical
estimates based on the total OC and cOC measurements. Fasting
insulin levels correlated positively with calculated proportion of
uncarboxylated OC (ucOC) (r = 0.176, p = 0.001) and this
correlation was significant also after adjustment for age, gender
and VLBW status (r = 0.193 p,0.001). The total OC correlated
negatively and the calculated ucOC positively with fasting insulin
when adjusted for age, gender, VLBW status and lean body mass
(r =20.156, p= 0.021 and r = 0.153, p= 0.007, respectively).
Elevated post-load glucose levels after OGTT is a validated
marker of impaired glucose regulation and predicts progression to
diabetes in subjects with normal fasting glucose [30]. Glucose
concentrations at 120 min were moderately associated with total
OC (p= 0.021) and cOC (p= 0.034) concentrations at 120 min.
However, the associations between glucose and OC were not
significant after any adjustments (Table 3).
Fasting insulin is a driver of homeostasis model assessment of
insulin resistance index HOMA-IR. HOMA-IR was strongly
correlated with OC and cOC at 0 min, independent of age,
gender, VLBW status and height (p,0.001 for all correlations)
and independent of lumbar spine BMD (r = 0.180, p = 0.010 and
r =20.277, p,0.001 for total OC and cOC, respectively). The
association between HOMA-IR and total OC was no longer
significant (p.0.05) when further adjusted for BMI, whereas
association to cOC remained significant (r =20.126, p = 0.038).
The acute glucose load during OGTT induced a significant
reduction in total OC and cOC levels in all subjects, the mean
(95% CI) decreases being 217.4% (219.0, 215.8) and 218.5%
(220.0, 216.9) for OC and cOC, respectively. The reduction of
OC and cOC values was similar in VLBW subjects and in controls
(for OC p=0.382, and for cOC p=0.708) (Figure 1). In the entire
cohort, the OGTT-induced reductions in OC values were not
associated with simultaneous increases in insulin levels (p = 0.54)
but were, however, weakly associated with OGTT-induced
increase in glucose levels (r =20.13, p= 0.022) (Table 4). Changes
in glucose and insulin concentrations during OGTT correlated
strongly with each other (r = 0.663, p,0.001, Table 4).
Discussion
Our study shows that fasting insulin levels are associated with
circulating OC values, particularly cOC, in young adults. All
subjects were non-diabetic but VLBW subjects in this cohort have
previously been reported to present with signs of impaired glucose
regulation [18]. The association between OC and fasting insulin
values was independent of age, gender and VLBW status,
indicating that OC may participate in long-term regulation of
glucose-insulin metabolism particularly in subjects with metabolic
challenges, such as the studied population with VLBW.
Impaired glucose tolerance is an indicator of impaired
regulation of glucose metabolism and reduced peripheral insulin
sensitivity. Post-load OC and cOC values in our study correlated
only weakly with glucose or insulin values at 120 min. Thus, we
suggest that OC does not seem to be the main mediator of acute
glucose regulation in humans during OGTT. Animal studies in
mice suggest that insulin signalling in osteoblasts increases the
Table 4. Standardized linear regression coefficients (Betastd)
between OGTT-induced changes (D120 min, from 0 to
120 min) in glucose, insulin and osteocalcin levels.
D120 min
Insulin
D120 min
Total OC
D120 min
cOC
D120’ minGlucose 0.663 *** 20.215 * 20.053
D120 min Insulin 20.034 20.065
D120 min Total OC 0.753***
P values are indicated with asterisks (*p,0.05, ***p,0.001).
doi:10.1371/journal.pone.0063036.t004
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secretion of OC and thereby promotes glucose homeostasis via
uncarboxylated OC and may thus prevent the development of
insulin resistance, glucose intolerance and abnormal weight gain
[3]. Several mechanisms have been proposed, including stimula-
tion of osteoblast differentiation and OC production, and
increased release of uncarboxylated osteocalcin from the bone
matrix due to increased bone resorption via alterations in RANK-
RANKL-OPG pathway [6,31]. It is unclear if similar regulatory
system is present in humans [9,32]. Furthermore, it is not known
how rapid the suggested effect of insulin is and whether 2-hour
OGTT is the best method to evaluate the effect. Our results do
not, however, exclude the possibility that insulin-induced OC may
regulate glucose and bone metabolism over a longer or shorter
time period than the interval used in this study. Our data indicate
that, in humans, OC and cOC levels rapidly and significantly
decrease following the glucose load but the magnitude is not
associated with increases in insulin levels.
Insulinotropic incretin hormones have been excluded as
potential key mediators for the immediate reduction in bone
formation after a meal in humans [33,34]. In animal studies,
however, glucose-dependent insulinotropic peptide (GIP) has been
observed to both inhibit bone resorption and stimulate bone
formation [35]. Thus, the OGTT-induced suppression of OC and
cOC observed in our study is likely to be mediated via a different
mechanism. In order to isolate the hormonal role of OC from its
role as a marker of bone formation we previously conducted a pilot
study in a subset of the cohort now studied [36], in which, we
assessed the changes in the markers of bone formation and
resorption together. We demonstrated that OGTT-induced
changes in OC are associated with OGTT-induced changes in
bone formation, but not resorption markers [36]. Regulation of
glucose metabolism in response to rapidly applied glucose load
might, however, differ from that observed after more physiological
intake of nutrients.
A limited number of studies have evaluated bone metabolism in
VLBW subjects. Some studies have reported increased OC in
subjects born with VLBW [37] while in another study (which did
not assess OC) no differences in formation or resorption markers
were observed [19]. In our study, OC and cOC were higher in
subjects born with VLBW and elevated OC levels could thus
partially explain the decreased insulin sensitivity in VLBW
subjects. This is somewhat contradictory to previous, mostly
preclinical findings in mice on the role of OC in energy
metabolism [4,5,6]. The baseline insulin and OC values were
also higher in female VLBW subjects than in females born at term
but there is no general, significant interaction between genders in
this VLBW cohort [18]. Also our data indicate that the gender-
specific differences are not significantly impacting the suggested
role of OC in acute glucose regulation. Subjects with VLBW are
smaller, shorter and have lower BMI than their peers and thus the
glucose load and total dose of glucose is proportionally higher for
them. Also subjects born at term but who had been small for their
gestational age have been shown in observational studies to
present with signs of impaired glucose regulation in adulthood
[38,39]. VLBW subjects as young adults have reduced BMD. This
might be due to their smaller size even if the measurements have
been corrected for bone size by estimation of volumetric bone
density [19,20]. However, additional adjustment for BMI, lean
body mass and fat-% did not significantly alter the results and thus
changes were mainly not attributable to body size or body
composition. In another study reporting early signs of decreased
insulin sensitivity, the body size or composition did not explain the
difference in regulation of insulin [19].
Based on the previously available data [40,41,42] and the
findings in this study, we suggest that the acute changes in glucose
homeostasis in humans are mostly regulated by non-skeletal
endocrine mechanisms. The difference between the results
observed in knockout mice and in humans can potentially be
explained additional to the species-specific differences in OC [9]
with the role of physiological concentrations of OC or ucOC.
While rodent models assess animals with dramatically altered OC
levels, clinical research is limited to differences within a normal
physiological range. It is unclear whether clinically meaningful
changes in markers of bone homeostasis can be observed during
an OGTT-induced physiological insulin release. Clamp studies in
humans isolating the effect of insulin on bone turnover markers
have failed to confirm the effect of physiological changes in insulin
on bone metabolism [43,44]. In a cross-sectional study in an
elderly population, OC was significantly correlated with insulin
resistance but no association with insulin secretion was observed
[12]. The regulatory role of bone metabolism and, in particular,
OC on glucose and insulin metabolism may be different in acute
and chronic metabolic challenges in humans.
The strengths of this study include the comprehensive and well-
described cohort of mostly normoglycemic young adults, with a
very limited number of potential confounding factors related to co-
morbidities or medications that may influence glycaemia or bone
turnover. Further, the subjects were studied close to the age of
peak bone mass attainment. Our study also has some limitations.
We did not directly measure ucOC but assessed total OC and
cOC and estimated the biological activity of OC based on these
values. This estimated method may not be sensitive enough to
detect small changes in the carboxylation status of OC. Further,
we did not have data on vitamin K intake or vitamin K status,
which is known to influence carboxylation of osteocalcin [9]. BMD
was assessed only in a subset of subjects and even if this portion of
subjects is high, it may not represent the entire original cohort of
VLBW subjects. However, eligible participants included in BMD
analysis or without BMD measurement were similar, as previously
described [20]. The criteria used for inclusion of subjects in this
study are not entirely the same as those applied when studying
glucose regulation [18] because the analysis of OC introduced
exclusion of subjects with no information or protocol violation
related to the length of fasting period prior to OGTT. Finally, the
serum sample volume was insufficient in this cohort for
measurements of other bone markers in order to distinguish the
putative hormonal role of OC from its role as a marker of bone
formation.
In summary, fasting insulin and HOMA-IR index values
predicted OC and cOC values in this cohort. This indicates an
association between OC and impaired glucose regulation and
early signs of peripheral insulin resistance. Our results also suggest
that circulating OC or cOC are not involved in the regulation of
acute changes in glucose homeostasis. We conclude that serum
OC may be involved in the long-term regulation of glucose
homeostasis but the role of OC in mediating acute responses to
glucose load is not pivotal.
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